编者按：中枢神经系统（CNS）疾病由于病理机制复杂，且药物入脑受到血脑屏障（BBB）的限制，一直被认为是药物研发领域的重大挑战。尽管困难重重，但FDA已在CNS领域先后批准多款小分子药物的临床批件或上市，凸显了小分子疗法在CNS治疗中的重要作用。

Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling. A pivotal trial failed to show benefit, and they had several other clinical failures as ...

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...

FREMONT, CA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ...

LONDON--(BUSINESS WIRE)--The global central nervous system (CNS) stimulant drugs market is expected to post a CAGR of over 5% during the period 2019-2023, according to the latest market research ...

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the ...

HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for ...

After being largely abandoned by big pharma, biotech, and investors for well over a decade, a renewed interest, along with a surge in funding opportunities, is being seen for advanced neuroscience ...